IAP (Inhibitor of Apoptosis) proteins, a family of anti-apoptotic proteins, play a crucial role in evading apoptosis because they have the ability to both block apoptosis-signaling pathways and promote survival. Eight members of this family (BIRC1/NAIP, BIRC2/cIAP1, BIRC3/cIAP2, BIRC4/XIAP, BIRC5/Survivin, BIRC6/Apollon, BIRC7/ML-IAP, and BIRC8/ILP2) have been identified in humans.
In determining the fate of a cell, IAP genes encode proteins that directly bind and inhibit caspases. Endogenous proteins (second mitochondrial activator of caspases and Omi) that are released from the mitochondria during apoptosis regulate the IAPs in turn. Members of the IAP protein family are frequently overexpressed in cancer and help tumor cells survive, resist chemotherapy, advance the disease, and have a poor prognosis. For the creation of new classes of cancer therapies, targeting important apoptosis regulators like IAPs is a tempting therapeutic approach.
IAPs have a significant impact on ubiquitin (Ub)-dependent pathways that modulate innate immune signaling by activating NF-B, though they are best known for their ability to control caspases. Several IAP family members influence cytokine production, signal transduction pathways, and cell survival to control innate and adaptive immunity. The function of cIAP1, cIAP2, and XIAP as ubiquitin ligases, whose targets have an impact on the NF-B and MAPK signaling pathways, is the primary mechanism by which the IAPs regulate immunity.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V8206 | ASTX-660 | 1799328-86-1 | ASTX660 is a novel and orally bioavailable, non-peptidomimetic antagonist of both X chromosome-linked inhibitor of apoptosis protein (XIAP) and cellular IAP 1 (cIAP1), with potential antineoplastic and pro-apoptoticctivities. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
